Haleon Pakistan

Haleon Pakistan Limited (formerly GlaxoSmithKline Consumer Healthcare Pakistan Limited) is a Pakistani public limited company that manufactures and markets consumer healthcare products. It is a subsidiary of the global consumer healthcare company, Haleon plc. The company is headquartered in Karachi and its shares are traded on the Pakistan Stock Exchange. ^[1]

History

Haleon Pakistan's history is closely linked to its parent company's evolution. The global entity, Haleon plc, was formed through the combination of consumer healthcare businesses from GSK, Novartis and Pfizer over the last decade^{[ when? ]}.

In 2015, GlaxoSmithKline Consumer Healthcare Pakistan Limited (GSKCH) was demerged from GlaxoSmithKline Pakistan Limited (GLAXO). ^[2] In 2016, GSKCH started operations as an independent company. ^[3] A year later, in 2017, GSKCH got listed on PSX. ^[3]

In Pakistan, the company, formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited, underwent a name change to align with the new global identity of Haleon, and listed as an independent company on the London and New York stock exchanges in July 2022. ^[4]

Operations and products

Haleon Pakistan operates in a single segment: consumer healthcare. The company's products are categorized into several key areas:

• Pain relief: This category includes well-known brands such as Panadol, an analgesic sold in Pakistan, and Voltaren, a topical pain reliever. ^[5]
• Oral health: The company offers oral care products with brands like Sensodyne for sensitive teeth and Parodontax for gum health. ^[5]
• Respiratory health: This portfolio includes products for cold and flu symptoms, such as Panadol Cold & Flu and the Actifed range. ^[5]
• Wellness and nutrition: This category covers products for digestive health and vitamins, minerals, and supplements (VMS). Brands include CaC 1000 Plus and ENO. ^[5]

The company has its head office in Karachi and a manufacturing facility in Jamshoro, Sindh. It also maintains regional sales offices in Lahore, Islamabad and Multan. In July 2025 Haleon Pakistan announced plans to expand its export markets and increase production capacity at its Jamshoro plant. ^[6]

Its CEO is Qawi Naseer, and its chairperson is Farhan Muhammad Haroon.^{[ citation needed ]}

References

1. Research, B. R. (15 August 2025). "Haleon Pakistan Limited". Brecorder. Retrieved 16 August 2025.
2. "GLAXO: earnings in red". Business Recorder. 1 September 2022. Retrieved 3 November 2022.
3. "GLAXO: earnings in red". Business Recorder. 1 September 2022. Retrieved 3 November 2022.
4. "Prospectus" (PDF). GSK plc. p. 15. Archived from the original (PDF) on 1 June 2022. Retrieved 10 June 2022.
5. "Our Consumer Healthcare Brands". Haleon. Archived from the original on 2 August 2023. Retrieved 19 July 2022.
6. Hanif, Usman (24 July 2025). "Haleon invests $12m in Panadol". The Express Tribune. Retrieved 16 August 2025.